drugset / Trial / NCT02053363

Tranexamic Acid Dosing in Adult Spinal Deformity Surgery

NCT02053363

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate two dosing protocols for tranexamic acid (TXA), an anti-fibrinolytic used to decrease blood loss in adult patients undergoing complex, reconstructive spinal fusion surgeries.

Timeline

Start
2014-03
Primary completion
2020-06-26
Completion
2020-06-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1 mg/kg Intravenous
Subject Tranexamic Acid Small molecule 5 mg/kg Intravenous

Indications

No indication recorded.